KR20010101922A - 고혈압 치료를 위한 약제학적 조성물 - Google Patents
고혈압 치료를 위한 약제학적 조성물 Download PDFInfo
- Publication number
- KR20010101922A KR20010101922A KR1020017009705A KR20017009705A KR20010101922A KR 20010101922 A KR20010101922 A KR 20010101922A KR 1020017009705 A KR1020017009705 A KR 1020017009705A KR 20017009705 A KR20017009705 A KR 20017009705A KR 20010101922 A KR20010101922 A KR 20010101922A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- hypertension
- treatment
- forms
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 201000004239 Secondary hypertension Diseases 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 208000019622 heart disease Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- -1 2,2-dimethyl-1,3-dioxolane-4 -yl Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract description 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 3
- 206010021143 Hypoxia Diseases 0.000 description 20
- 230000007954 hypoxia Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 210000001147 pulmonary artery Anatomy 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000004872 arterial blood pressure Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 6
- 238000007634 remodeling Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 150000001991 dicarboxylic acids Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004088 pulmonary circulation Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- QJJDBWAEIBNZPQ-UHFFFAOYSA-N 2-(3h-1,2-benzothiazepin-2-yl)acetic acid Chemical class S1N(CC(=O)O)CC=CC2=CC=CC=C21 QJJDBWAEIBNZPQ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
- 229950002544 aminorex Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002236 anti-hypertrophic effect Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906310.9 | 1999-02-16 | ||
| DE19906310A DE19906310A1 (de) | 1999-02-16 | 1999-02-16 | Arzneimittel zur Behandlung von Bluthochdruck |
| PCT/EP2000/001068 WO2000048601A1 (de) | 1999-02-16 | 2000-02-10 | Arzneimittel zur behandlung von bluthochdruck |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077001387A Division KR100797665B1 (ko) | 1999-02-16 | 2000-02-10 | 고혈압 치료를 위한 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010101922A true KR20010101922A (ko) | 2001-11-15 |
Family
ID=7897580
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020017009705A Ceased KR20010101922A (ko) | 1999-02-16 | 2000-02-10 | 고혈압 치료를 위한 약제학적 조성물 |
| KR1020077001387A Expired - Fee Related KR100797665B1 (ko) | 1999-02-16 | 2000-02-10 | 고혈압 치료를 위한 약제학적 조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077001387A Expired - Fee Related KR100797665B1 (ko) | 1999-02-16 | 2000-02-10 | 고혈압 치료를 위한 약제학적 조성물 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6482820B2 (https=) |
| EP (1) | EP1154777B1 (https=) |
| JP (1) | JP2002537258A (https=) |
| KR (2) | KR20010101922A (https=) |
| CN (1) | CN1198619C (https=) |
| AR (1) | AR036864A1 (https=) |
| AT (1) | ATE295174T1 (https=) |
| AU (1) | AU773240C (https=) |
| BR (1) | BR0008260A (https=) |
| CA (1) | CA2362273C (https=) |
| CZ (1) | CZ301499B6 (https=) |
| DE (2) | DE19906310A1 (https=) |
| DZ (1) | DZ3014A1 (https=) |
| ES (1) | ES2238268T3 (https=) |
| HK (1) | HK1042247B (https=) |
| HU (1) | HUP0105491A3 (https=) |
| IL (1) | IL144622A (https=) |
| NO (1) | NO329588B1 (https=) |
| NZ (1) | NZ514058A (https=) |
| PL (1) | PL195283B1 (https=) |
| PT (1) | PT1154777E (https=) |
| RU (1) | RU2270679C2 (https=) |
| SK (1) | SK287254B6 (https=) |
| TR (1) | TR200102386T2 (https=) |
| TW (1) | TWI221770B (https=) |
| UA (1) | UA63032C2 (https=) |
| WO (1) | WO2000048601A1 (https=) |
| ZA (1) | ZA200105828B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| DE60040089D1 (de) * | 1999-11-19 | 2008-10-09 | Solvay Pharm Bv | Menschliches homolog aus der familie der metalloproteasen |
| ATE367815T1 (de) * | 2000-10-04 | 2007-08-15 | Astellas Pharma Inc | Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension |
| JP2004536063A (ja) * | 2001-05-18 | 2004-12-02 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬の製造における組み合わせたｎｅｐ／ｍｐ−抑制活性を有する化合物の使用 |
| AP1758A (en) * | 2001-09-10 | 2007-07-30 | Tibotec Pharm Ltd | Method for the preparation of hexahydro-furo [2,3-b]furan-3-ol. |
| RU2303041C2 (ru) | 2002-01-16 | 2007-07-20 | Солвей Фармасьютикалс Б.В. | Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений |
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| WO2004062692A1 (en) * | 2003-01-13 | 2004-07-29 | Solvay Pharmaceuticals B.V. | Formulation of poorly water-soluble active substances |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| SA04250283B1 (ar) * | 2003-09-26 | 2008-05-26 | سولفاي فارماسيتيكالز جي أم بي أتش | مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| JP4824573B2 (ja) | 2003-11-18 | 2011-11-30 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物 |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| RU2410118C2 (ru) | 2004-12-15 | 2011-01-27 | Зольвай Фармасьютиклз Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| US20070292503A1 (en) * | 2006-06-16 | 2007-12-20 | Gorissen Henricus R | Oral pharmaceutical composition of poorly water-soluble active substance |
| US20070299054A1 (en) * | 2006-06-22 | 2007-12-27 | Rajesh Jain | Oral pharmaceutical composition of a poorly water-soluble active agent |
| KR20170005155A (ko) * | 2008-01-31 | 2017-01-11 | 반더빌트유니버시티 | 폐의 용태에 따른 치료 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| CA1337400C (en) * | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
| US5087702A (en) * | 1991-01-30 | 1992-02-11 | Merck & Co., Inc. | Microbial transformation process for producing an antihypertensive product |
| US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
-
1999
- 1999-02-16 DE DE19906310A patent/DE19906310A1/de not_active Ceased
-
2000
- 2000-01-20 AR ARP000100257A patent/AR036864A1/es unknown
- 2000-01-21 TW TW089101041A patent/TWI221770B/zh not_active IP Right Cessation
- 2000-02-10 DE DE50010284T patent/DE50010284D1/de not_active Expired - Lifetime
- 2000-02-10 BR BR0008260-0A patent/BR0008260A/pt not_active Application Discontinuation
- 2000-02-10 HU HU0105491A patent/HUP0105491A3/hu unknown
- 2000-02-10 RU RU2001124604/15A patent/RU2270679C2/ru not_active IP Right Cessation
- 2000-02-10 NZ NZ514058A patent/NZ514058A/en not_active IP Right Cessation
- 2000-02-10 JP JP2000599393A patent/JP2002537258A/ja active Pending
- 2000-02-10 PT PT00903681T patent/PT1154777E/pt unknown
- 2000-02-10 CA CA2362273A patent/CA2362273C/en not_active Expired - Fee Related
- 2000-02-10 AU AU25476/00A patent/AU773240C/en not_active Ceased
- 2000-02-10 KR KR1020017009705A patent/KR20010101922A/ko not_active Ceased
- 2000-02-10 ES ES00903681T patent/ES2238268T3/es not_active Expired - Lifetime
- 2000-02-10 CN CNB008038236A patent/CN1198619C/zh not_active Expired - Fee Related
- 2000-02-10 EP EP00903681A patent/EP1154777B1/de not_active Expired - Lifetime
- 2000-02-10 PL PL00350167A patent/PL195283B1/pl not_active IP Right Cessation
- 2000-02-10 KR KR1020077001387A patent/KR100797665B1/ko not_active Expired - Fee Related
- 2000-02-10 HK HK02104121.2A patent/HK1042247B/zh not_active IP Right Cessation
- 2000-02-10 TR TR2001/02386T patent/TR200102386T2/xx unknown
- 2000-02-10 CZ CZ20012672A patent/CZ301499B6/cs not_active IP Right Cessation
- 2000-02-10 SK SK1082-2001A patent/SK287254B6/sk not_active IP Right Cessation
- 2000-02-10 AT AT00903681T patent/ATE295174T1/de active
- 2000-02-10 WO PCT/EP2000/001068 patent/WO2000048601A1/de not_active Ceased
- 2000-02-13 DZ DZ000029A patent/DZ3014A1/xx active
- 2000-10-02 UA UA2001096336A patent/UA63032C2/uk unknown
-
2001
- 2001-07-16 ZA ZA200105828A patent/ZA200105828B/en unknown
- 2001-07-30 IL IL144622A patent/IL144622A/en not_active IP Right Cessation
- 2001-08-15 NO NO20013958A patent/NO329588B1/no not_active IP Right Cessation
- 2001-08-16 US US09/930,186 patent/US6482820B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100797665B1 (ko) | 고혈압 치료를 위한 약제학적 조성물 | |
| JP4819224B2 (ja) | ベンゾインデンプロスタグランジンの吸入送達法 | |
| JP2002537258A5 (https=) | ||
| HU219404B (hu) | Eljárás kardiális és vaszkuláris hipertrófia és/vagy hiperplazia kezelésére alkalmas angiotenzin-II-receptor blokkoló hatású vegyületet tartalmazó gyógyszerkészítmények előállítására | |
| US20030040512A1 (en) | Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances | |
| HU207220B (en) | Process for producing pharmaceutical composition for diminishing enhanced pressure of the pulmonary circulation | |
| EP0425956A2 (en) | ACE inhibitors for use for stabilizing or causing regression of atherosclerosis in coronary arteries | |
| JPH03151329A (ja) | 冠状血管内皮の血管弛緩作用回復および冠状血管痙攣防止用剤 | |
| USH1139H (en) | Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination | |
| JP4824573B2 (ja) | 腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物 | |
| EP0612523B1 (en) | Vascular hypertrophy suppressor | |
| PT86292B (pt) | Processo para a preparacao de uma composicao farmaceutica anti-hipertensora, contendo um activador de canal de potassio (por exemplo, cromacalina) e um inibidor de ace (por exemplo, enalapril) | |
| US3821381A (en) | Method of treatment | |
| MXPA01008164A (en) | Medicament for treating hypertension | |
| JP2532918B2 (ja) | グアニジノ安息香酸誘導体を有効成分として含有する抗動脈硬化剤 | |
| JPH08291075A (ja) | 癌転移阻害剤 | |
| JPH03130227A (ja) | カリウム低減・排泄剤 | |
| JPH08165239A (ja) | 抗動脈硬化剤 | |
| CA2237620A1 (en) | Platelet function increment agent and therapeutic method for thrombocytopathy | |
| JPH02145520A (ja) | 臓器拒絶反応の予防および治療用医薬の製造のためのホモピペラジンの使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20010801 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20050111 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060627 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20061227 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060627 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| J201 | Request for trial against refusal decision | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20070119 |
|
| PJ0201 | Trial against decision of rejection |
Patent event date: 20070119 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20061227 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20070625 Appeal identifier: 2007101000729 Request date: 20070119 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070119 Effective date: 20070625 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20070626 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20070119 Decision date: 20070625 Appeal identifier: 2007101000729 |